Radiotherapy for limb neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study involves patients treated at the European Institute of Oncology who receive radiotherapy for neoplasms located in the upper or lower limbs. Approximately 60% of patients with neoplasms undergo radiotherapy as part of their treatment, which may be combined with other systemic or surgical therapies. The study aims to collect data on treatment outcomes and tolerability to identify optimal treatment strategies for various types of bone and soft tissue tumors, as well as metastatic conditions. By analyzing this data, the research seeks to enhance understanding of effective radiotherapy protocols.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the upper and lower limbs for:

   Primary bone tumors, Primary soft tissue tumors, Primary tumors of the cardio-circulatory system, Primary tumors of the lymphatic system, Primary tumors of the nervous system and skin, Secondary metastases from various origins localized in that district.
2. Signed informed consent

Exclusion Criteria:

1\. Radiotherapy in districts other than limbs.

Where it's running

• European Institute of Oncology
  Milan, Italy Recruiting

Study contacts

• Principal investigator: Barbara Alicja Jereczek — European Institute of Oncology
• Study coordinator: Barbara Alicja Jereczek
• Email: barbara.jereczek@ieo.it
• Phone: +39 02 57489326

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Stress and anxiety around biopsy and treatment for suspected bone or soft tissue tumors

  This study will follow adults undergoing a biopsy for a suspected bone or soft tissue tumor to see how their stress and anxiety levels change before the biopsy, after receiving the diagnosis, and at treatment start.

  Recruiting Istanbul University · Istanbul · NCT07727434

• Prophylactic Radiotherapy to Prevent Bone Complications in Metastatic Cancers

  This study tests whether giving early radiotherapy to high-risk bone metastases, in addition to standard care, can reduce bone-related problems in adults with metastatic solid cancers.

  Recruiting Phase 2 Institute of Oncology Ljubljana · Ljubljana · NCT07540650

• Focused high-dose SBRT for spinal tumors

  This program will try focused high-dose SBRT for adults with spinal metastases to track side effects and local tumor control during routine care.

  Recruiting at 2 sites Institute of Oncology Ljubljana · Ljubljana and 1 other locations · NCT07429422

• Registry for people with symptomatic bone metastases

  This registry collects health information from adults with symptomatic bone metastases who need treatment for painful or unstable bone lesions to learn more about outcomes and care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07391410

• One-visit, simulation-free single-dose radiation for painful bone metastases

  This trial tests whether adults with one or two painful bone metastases can get pain-relieving radiation in a single visit using a simulation-free planning approach.

  Recruiting University of Utah · Salt Lake City, Utah · NCT07202273

• Dual Energy CT to Delineate Tumors and Organs at Risk in Radiotherapy

  This study tests whether dual-energy CT can delineate tumors and nearby critical tissues as well as MRI for patients needing radiotherapy.

  Recruiting at 2 sites Aalborg University Hospital · Aalborg and 2 other locations · NCT07185958

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.